| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/25/2009 | EP2038290A1 Modulators of toll-like receptor 7 |
| 03/25/2009 | EP2038289A2 Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
| 03/25/2009 | EP2038288A1 Novel 4-amino-3-(-azolyl-phenoxymethyl)-thienoý3,2¨pyridine-7-carboxylic acid derivatives |
| 03/25/2009 | EP2038287A1 Spiro[benzopyran]or spiro[benzofuran]derivatives which inhibit the sigma receptor |
| 03/25/2009 | EP2038286A1 Pyrro[1,2-b]pyridazinone compounds |
| 03/25/2009 | EP2038285A2 Adenosine a2a receptor antagonists |
| 03/25/2009 | EP2038284A2 Heterobicylic metalloprotease inhibitors |
| 03/25/2009 | EP2038283A2 Heterobicyclic metalloprotease inhibitors |
| 03/25/2009 | EP2038282A1 Salts of pyrrolopyrimidinone derivatives and process for preparing the same |
| 03/25/2009 | EP2038281A2 Nicotinic agonists selective for the alpha7 receptor subtype, the process for the preparation thereof and pharmaceutical compositions therefrom |
| 03/25/2009 | EP2038280A2 Fused, tricyclic sulfonamide inhibitors of gamma secretase |
| 03/25/2009 | EP2038279A2 Substituted pyrazolo [1,5- alpha] pyridine compounds and their methods of use |
| 03/25/2009 | EP2038278A2 Thiazoline and oxazoline derivatives and their methods of use |
| 03/25/2009 | EP2038277A2 Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound |
| 03/25/2009 | EP2038275A2 Novel pyridazine compound and use thereof |
| 03/25/2009 | EP2038274A2 Transcription factor modulating compounds and methods of use thereof |
| 03/25/2009 | EP2038269A1 Substituted benzamide modulators of the histamine h3 receptor |
| 03/25/2009 | EP2038267A2 Thiadiazolidinone inhibitors of ptpase |
| 03/25/2009 | EP2038266A2 Compounds as cannabinoid receptor ligands and uses thereof |
| 03/25/2009 | EP2038265A2 Human protein tyrosine phosphatase inhibitors and methods of use |
| 03/25/2009 | EP2038264A1 Tetrazole-substituted arylamides |
| 03/25/2009 | EP2038262A2 Triazole compounds that modulate hsp90 activity |
| 03/25/2009 | EP2038259A1 Benzimidazole derivatives, method for the production thereof, their use as fxr agonists and pharmaceutical preparations containing the same |
| 03/25/2009 | EP2038258A1 5-urea substituted naphthalimide derivatives, methods of production and pharmaceutical compositions for treating cancer |
| 03/25/2009 | EP2038257A1 N-oxides of diarylurea derivatives and their use as chk1 inhibitors for the treatment of cancer |
| 03/25/2009 | EP2038256A1 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ']-bipyridine and its use as a medicament |
| 03/25/2009 | EP2038255A2 Pharmaceutical use of substituted piperidine carboxamides |
| 03/25/2009 | EP2038254A2 Bicyclic compositions and methods for modulating a kinase cascade |
| 03/25/2009 | EP2038253A1 Biphenyl derivatives and their use in treating hepatitis c |
| 03/25/2009 | EP2038252A2 Substituted acylanilides and methods of use thereof |
| 03/25/2009 | EP2038251A1 Positively charged water-soluble prodrugs of aspirin |
| 03/25/2009 | EP2038248A2 Combination of ceramide and oxaliplatin for inducing cell death and uses thereof in treating cancer |
| 03/25/2009 | EP2038247A2 Site-specific inhibitors of histone methyltransferase [hmtase] and process of preparation thereof |
| 03/25/2009 | EP2038041A2 Therapeutic compounds and their use in cancer |
| 03/25/2009 | EP2037967A2 Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph |
| 03/25/2009 | EP2037965A2 Pharmaceutical composition with synergistic anticonvulsant effect |
| 03/25/2009 | EP2037964A2 Combination preparations comprising bifeprunox and l-dopa |
| 03/25/2009 | EP2037963A2 Soft tissue repair and regeneration using stem cell products |
| 03/25/2009 | EP2037951A2 Methods and compositions for treating ophthalmic conditions via modulation of megalin activity |
| 03/25/2009 | EP2037942A2 Polymeric biosurfactants |
| 03/25/2009 | EP2037941A1 Cobalamin compositions and methods for treating or preventing mucositis |
| 03/25/2009 | EP2037939A1 An anticancer drug comprising inhibitor of tmprss4 |
| 03/25/2009 | EP2037938A2 Drug delivery polymer with hydrochloride salt of clindamycin |
| 03/25/2009 | EP2037937A2 Tri and tetra-oligo-saccharides suitable as agglutination agents for enteric pathogens |
| 03/25/2009 | EP2037936A2 Method of treating and preventing secondary hyperparathyroidism |
| 03/25/2009 | EP2037935A1 Pharmaceutical preparations for contraception and for preventing the risk of congenital malformations |
| 03/25/2009 | EP2037934A2 An anti-viral composition for the topical treatment of herpes labialis (cold sores) and method for use thereof |
| 03/25/2009 | EP2037933A2 Combinations comprising staurosprorines |
| 03/25/2009 | EP2037932A1 Chemotherapeutic compounds for selectively targeting tumor cells with fr type receptors |
| 03/25/2009 | EP2037931A2 Pharmaceutical combinations of pk inhibitors and other active agents |
| 03/25/2009 | EP2037930A1 The use of 1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension |
| 03/25/2009 | EP2037928A2 Methods for treating atherosclerosis |
| 03/25/2009 | EP2037927A1 Flibanserin for the treatment of urinary incontinence and related diseases |
| 03/25/2009 | EP2037926A1 Use of pkc inhibitors in diabetic complications |
| 03/25/2009 | EP2037925A1 Combinations comprising 5ht6 modulators and cholinesterase inhibitors |
| 03/25/2009 | EP2037924A2 Bicyclic heteroaryl inhibitors of pde4 |
| 03/25/2009 | EP2037923A2 Antioxidant combinations for use in ruminant feed rations having a fat source |
| 03/25/2009 | EP2037922A2 Prolyl hydroxylase inhibitors |
| 03/25/2009 | EP2037921A2 Sugar-free storage-stable antihistaminic syrups |
| 03/25/2009 | EP2037920A1 Use of a cannabinoid cb1 receptor antagonist for preparation of drugs useful for the prevention and treatment of benign prostatic hypertrophy |
| 03/25/2009 | EP2037919A2 Method of using substituted piperidines that increase p53 activity |
| 03/25/2009 | EP2037918A2 Pharmaceutical formulations of pimavanserin |
| 03/25/2009 | EP2037917A1 Pharmaceutical composition comprising amlodipine and losartan |
| 03/25/2009 | EP2037916A2 Pure isomers of tritoqualine |
| 03/25/2009 | EP2037915A2 Phenol derivatives for the treatment of respiratory diseases |
| 03/25/2009 | EP2037914A1 A suspension comprising benzimidazole carbamate and a polysorbate |
| 03/25/2009 | EP2037913A2 Treatment of erectile dysfunction and libido enhancement |
| 03/25/2009 | EP2037912A2 Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |
| 03/25/2009 | EP2037911A2 Composition comprising chrysine and cholic acid for reduction of weight, acceleration of lipolysis and/or restriction of calories |
| 03/25/2009 | EP2037910A1 Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia |
| 03/25/2009 | EP2037909A2 Solid dose formulations of a thrombin receptor antagonist |
| 03/25/2009 | EP2037908A2 Method for treatment of wound using aganocides |
| 03/25/2009 | EP2037907A2 Ruminant feedstock dietary supplement |
| 03/25/2009 | EP2037906A1 S1p receptor modulators for treating multiple sclerosis |
| 03/25/2009 | EP2037905A2 Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| 03/25/2009 | EP2037904A1 Basic acetophenones as inhibitors of no-synthases |
| 03/25/2009 | EP2037903A1 Combination methods of treating cancer |
| 03/25/2009 | EP2037902A1 Cannabinoids for use in the treatment of neuropathic pain |
| 03/25/2009 | EP2037901A1 Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression |
| 03/25/2009 | EP2037900A2 Treatment of excess sebum production |
| 03/25/2009 | EP2037898A2 Ibuprofen-containing liquid filled hard capsules |
| 03/25/2009 | EP2037897A2 An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof |
| 03/25/2009 | EP2037894A2 Compositions with controlled pharmacokinetics |
| 03/25/2009 | EP2037893A2 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same |
| 03/25/2009 | EP2037892A2 Modified factor viii and factor ix genes and vectors for gene therapy |
| 03/25/2009 | EP2037891A1 Tablets comprising candesartan cilexetil |
| 03/25/2009 | EP2037890A1 Oral pharmaceutical composition of a poorly water-soluble active substance |
| 03/25/2009 | EP2037889A2 Nanostructured lipid carriers containing riluzole and pharmaceutical formulations containing said particles |
| 03/25/2009 | EP2037888A2 Active agent formulations, methods of making, and methods of use |
| 03/25/2009 | EP2037887A2 Oral controlled release formulations of an interleukin-1 beta converting enzyme inhibitor |
| 03/25/2009 | EP2037885A1 Low dose sublingual tablets of opioid analgesics and preparation process |
| 03/25/2009 | EP2037884A2 Sustained release formulations of aromatase inhibitors |
| 03/25/2009 | EP2037883A2 Inhalant powder containing phenylalanine |
| 03/25/2009 | EP2037881A1 Steroid-containing sustained release intraocular implants and related methods |
| 03/25/2009 | EP2037879A1 Compositions of glycopyrronium salt for inhalation |
| 03/25/2009 | EP2037874A1 Compositions with several hyaluronic acid fractions for cosmetic and medical uses |
| 03/25/2009 | EP2037873A2 Dermatological anti-wrinkle agent |
| 03/25/2009 | EP2037872A2 Compositions comprising betulonic acid |
| 03/25/2009 | EP2037762A1 Method to prepare pure curcumin |
| 03/25/2009 | EP2037742A2 Prevention of nuclear, solar, and other radiation-induced tissue damage |